Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$4.1B
33M shares
52-week range
$100.85 – $212.00
23% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
www.irhythmtech.comNo one on the platform currently holds IRTC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 53,800 | $6.3M |
| Bridgewater Associatesas of 2025-12-31 | 11,348 | $2.0M |
No one on the platform has traded IRTC yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IRTC Investors: $45M Settlement Now Accepting Claims A $45M settlement has been reached in the iRhythm case involving claims about its Zio AT device, including data accuracy and its use in high-risk patients. The company later faced FDA and DOJ scrutiny over the device. Eligible $IRTC investors who purchased shares between 2022 and 2024 can now submit a claim: https://11th.com/cases/irhythm-investor-settlement
View on StockTwits ↗$IRTC Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.01 up 97.73% YoY • Reported revenue of $224.17M up 20.08% YoY • For the full year 2026, iRhythm Technologies Inc. expects revenue between $880 million and $890 million and adjusted EBITDA margin between 13.0% and 14.0%, reflecting volume-led growth and gross margin expansion.
View on StockTwits ↗$IRTC iRhythm Technologies Q2 Adj. EPS $0.58 Beats $(0.00) Estimate, Sales $224.172M Beat $219.324M Estimate
View on StockTwits ↗$IRTC reports after the close, Estimize Consensus +0.08 EPS and +6.33M Revs compared to WS http://www.estimize.com/irtc/fq2-2026?utm_conten
View on StockTwits ↗$IRTC investors there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/irhythm-investor-settlement
View on StockTwits ↗Imagine buying $IRTC at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $IRTC investors out there, we’ve got some important news: a $45 million investor settlement is now open for claims from shareholders who purchased shares between 2022 and 2024. You can check if you’re eligible and claim your share: https://11th.com/cases/irhythm-investor-settlement
View on StockTwits ↗Settlement Update: iRhythm Technologies ($IRTC) The proposed $45M iRhythm settlement has advanced to the Stipulation of Settlement stage, meaning the parties have formally agreed to resolve the case and are now seeking court approval. The case covers investors who purchased $IRTC shares between July 25, 2022 and August 29, 2024. We have every detail, including how investors can get paid: https://11th.com/cases/irhythm-investor-settlement
View on StockTwits ↗https://marketbeat.com/a/8661047/ $IRTC iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
View on StockTwits ↗$IRTC Current Stock Price: $118.11 Contracts to trade: $120.0 IRTC May 15 2026 Call Entry: $2.35 Exit: $3.21 ROI: 37% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$IRTC Share Price: $120.50 Contract Selected: Nov 20, 2026 $140 Calls Buy Zone: $8.84 – $10.92 Target Zone: $14.47 – $17.69 Potential Upside: 55% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$IRTC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.43 up 55.67% YoY • Reported revenue of $199.39M up 25.66% YoY • iRhythm increased its fiscal year 2026 revenue guidance to a range of $875M to $885M and adjusted EBITDA margin guidance to 12.0% to 13.0%, reflecting continued volume-led growth and operating leverage.
View on StockTwits ↗$IRTC reports after the close, Estimize Consensus +0.03 EPS and +3.67M Revs compared to WS http://www.estimize.com/irtc/fq1-2026?utm_conten
View on StockTwits ↗More low scores from the momentum scanner, but some exciting news. These are setups to watch and study, not trade recommendations. $CRMD Score 90 (BREAKOUT WATCH!), $ADM Score 93, $VST Score 73, $MGM Score 70, $IRTC Score 70
View on StockTwits ↗$IRTC iRhythm Technologies (NASDAQ: IRTC) is revolutionizing heart monitoring with AI-powered diagnostics. With strong clinical data and rising adoption, this stock could be a major player in the future of digital healthcare. https://biotechhealthx.com/biotech-news/is-it-a-great-move-to-invest-in-irhythm-technologies-irtc/
View on StockTwits ↗2 Under-the-Radar Wearable AI Stocks Analysts Are Bullish On https://www.tipranks.com/news/article/2-under-the-radar-wearable-ai-stocks-analysts-are-bullish-on $AMBQ $IRTC
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $881M | +19.1% | $-0.01 | $-0.02–$0.01 | — | 7 |
| 2027 | $1.0B | +15.7% | $1.12 | $0.88–$1.29 | 113.0× | 7 |
| 2028 | $1.2B | +15.6% | $2.34 | $2.11–$2.56 | 54.0× | 5 |
| 2029 | $1.4B | +17.0% | $4.10 | $4.04–$4.15 | 30.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.04 | $-0.01 | +75.0% |
| 2026-04-30 | $-0.56 | $-0.43 | +23.2% |
| 2026-02-19 | $0.02 | $0.17 | +750.0% |
| 2025-10-30 | $-0.36 | $-0.06 | +83.3% |
| 2025-07-31 | $-0.53 | $-0.32 | +39.6% |
| 2025-05-01 | $-0.89 | $-0.95 | -6.7% |
| 2025-02-20 | $-0.29 | $0.01 | +103.4% |
| 2024-10-30 | $-0.55 |
| $-1.26 |
| -129.1% |
| +2.46% |
| $12.1B |
| — |
| CHEChemed Corporation | $532.88 | -0.80% | $7.0B | — |
| CRSPCRISPR Therapeutics AG | $53.55 | -0.81% | $5.2B | — |
Source: Financial Modeling Prep · peers by sector/industry